showed that CXCL12 enhances the resistance of chronic myelogenous leukemia cells to Adriamycin by increasing the expression of CXCR4 and activating the downstream AKT/NF-κB pathway.39 The gene discussed is AKT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.